BR112015015788A2 - formulações farmacêuticas de nano-emulsão tópicas líquidas - Google Patents

formulações farmacêuticas de nano-emulsão tópicas líquidas

Info

Publication number
BR112015015788A2
BR112015015788A2 BR112015015788A BR112015015788A BR112015015788A2 BR 112015015788 A2 BR112015015788 A2 BR 112015015788A2 BR 112015015788 A BR112015015788 A BR 112015015788A BR 112015015788 A BR112015015788 A BR 112015015788A BR 112015015788 A2 BR112015015788 A2 BR 112015015788A2
Authority
BR
Brazil
Prior art keywords
active ingredient
pharmaceutical formulations
nano
emulsion pharmaceutical
particle size
Prior art date
Application number
BR112015015788A
Other languages
English (en)
Inventor
Jordan Chris
L Jordan Frederick
Original Assignee
Jrx Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jrx Biotechnology Inc filed Critical Jrx Biotechnology Inc
Publication of BR112015015788A2 publication Critical patent/BR112015015788A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo da patente de invenã§ã£o para: “formulaã‡ã•es farmacãšuticas de nano-emulsãƒo tã“picas lãquidas”. os aspectos da presente invenã§ã£o referem-se a composiã§ãµes que sã£o ãºteis para o fornecimento de um ingrediente ativo a um indivã­duo. algumas modalidades sã£o formuladas com um ingrediente ativo, incluindo, por exemplo, um fã¡rmaco anti-inflamatã³rio nã£o-esteroidal (aine), tais como aspirina, ibuprofeno, cetoprofeno, ou naproxeno, acetaminofeno, ou um polipeptã­deo ou uma proteã­na, tal como insulina, em que o ingrediente ativo ã© estabilizado e maior do que 90% das partã­culas do ingrediente ativo tãªm um tamanho de partã­cula que ã© inferior a ou igual a ou qualquer nãºmero entre 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, ou 4 nanã´metros, ou menores, conforme determinado por dispersã£o dinã¢mica de luz (dls), usando um mã©todo de cã¡lculo de distribuiã§ã£o de tamanho de partã­cula de volume ponderado.
BR112015015788A 2012-12-31 2013-12-27 formulações farmacêuticas de nano-emulsão tópicas líquidas BR112015015788A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261748036P 2012-12-31 2012-12-31
US201361758726P 2013-01-30 2013-01-30
PCT/US2013/077985 WO2014106048A2 (en) 2012-12-31 2013-12-27 Liquid topical pharmaceutical nano-emulsion formulations

Publications (1)

Publication Number Publication Date
BR112015015788A2 true BR112015015788A2 (pt) 2017-07-11

Family

ID=51022202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015788A BR112015015788A2 (pt) 2012-12-31 2013-12-27 formulações farmacêuticas de nano-emulsão tópicas líquidas

Country Status (11)

Country Link
US (2) US20150374835A1 (pt)
EP (1) EP2938324B1 (pt)
JP (1) JP6403686B2 (pt)
KR (1) KR20150102058A (pt)
CN (2) CN105209011B (pt)
BR (1) BR112015015788A2 (pt)
EA (1) EA201591015A1 (pt)
ES (1) ES2969933T3 (pt)
HK (2) HK1216719A1 (pt)
SG (1) SG11201505076UA (pt)
WO (1) WO2014106048A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
EP3558269A1 (en) * 2016-12-21 2019-10-30 Dukebox SP. Z O.O. A method of manufacturing a water-in-oil emulsion of nanoparticles of paracetamol
US11634368B2 (en) * 2018-03-28 2023-04-25 Jrx Biotechnology, Inc. Agricultural compositions
KR102117651B1 (ko) 2018-04-27 2020-06-02 대구가톨릭대학교산학협력단 항산화, 주름개선 또는 염증개선용 한방 조성물 및 이를 포함하는 화장료 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
JP2000506062A (ja) 1996-03-01 2000-05-23 株式会社 荏原製作所 電子ビーム照射による脱硫方法及び装置
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
US7220427B2 (en) * 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
FR2787703B1 (fr) * 1998-12-29 2001-01-26 Oreal Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
EP1684681B1 (en) * 2003-10-10 2018-10-24 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
ES2560449T3 (es) * 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
US20050271752A1 (en) * 2004-06-04 2005-12-08 Roth Ivar E Antifungal products and method of use
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006113668A1 (en) * 2005-04-15 2006-10-26 University Of South Florida A method of transdermal drug delivery using hyaluronic acid nanoparticles
WO2009021526A1 (de) * 2007-07-25 2009-02-19 S & V Technologies Ag Hyaluronsäuredispersion, herstellung und anwendung
GB2451811A (en) * 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
DE102008034944B4 (de) * 2008-07-26 2017-03-16 Arivine Pharma Ag Mikroemulsion

Also Published As

Publication number Publication date
HK1218723A1 (zh) 2017-03-10
WO2014106048A3 (en) 2014-08-21
CN110201180A (zh) 2019-09-06
EP2938324A2 (en) 2015-11-04
SG11201505076UA (en) 2015-07-30
US20200009257A1 (en) 2020-01-09
EP2938324B1 (en) 2023-11-08
ES2969933T3 (es) 2024-05-23
CN105209011A (zh) 2015-12-30
EP2938324A4 (en) 2016-09-28
WO2014106048A2 (en) 2014-07-03
JP2016508141A (ja) 2016-03-17
US20150374835A1 (en) 2015-12-31
CN105209011B (zh) 2019-06-25
EA201591015A1 (ru) 2016-05-31
JP6403686B2 (ja) 2018-10-10
HK1216719A1 (zh) 2016-12-02
KR20150102058A (ko) 2015-09-04

Similar Documents

Publication Publication Date Title
BR112015015788A2 (pt) formulações farmacêuticas de nano-emulsão tópicas líquidas
MX2013007807A (es) Emulsiones de aceite/agua que comprenden alcanos semifluorados.
BR112012023638A2 (pt) Sistema de entrega, composição cosmética, farmacêutica e/ou alimentar e uso da composição cosmética, farmacêutica e/ou alimentar
CL2017001364A1 (es) Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos.
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
UA115121C2 (uk) Сукупність частинок, які містять каротиноїдну сполуку і молекулу, що транспортується, та їх застосування
BR112014030820A2 (pt) formulação de anticorpos
BR112013000392B8 (pt) Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
WO2017037075A8 (de) Zusammensetzung enthaltend einen extrakt aus echinacea und linolsäurederivate
BR112015012920A2 (pt) gel oral para dor de dente e sensibilidade
BR112014031841A2 (pt) formulação farmacêutica
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
BR112015012960A2 (pt) gel oral para o alívio da dor de dente
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
AR083117A1 (es) Peptidos del veneno de escorpion rhopalurus junceus y composicion farmaceutica
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno
BR112014007410A2 (pt) preparação cosmética compreendendo substâncias pulverizadas para melhorar a fixação do perfume
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"
WO2016075704A3 (en) Stable topical pharmaceutical compositions comprising gabapentin
GT201200295A (es) Combinacion de un aine y un aminoácido
UA107631C2 (uk) Фармацевтична композиція лікарського засобу седативної і спазмолітичної дії у формі м'яких желатинових капсул (варіанти)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements